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bjections from die-hard skeptics notwithstanding, cardiac
esynchronization therapy (CRT) improves symptoms, ven-
ricular performance, functional capacity, quality of life, and
urvival in patients with moderate to severe congestive heart
ailure (CHF). Now, Yannopoulos et al. (1) propose that
RT also decreases the frequency and duration of atrial
rrhythmia. The authors, in the current issue of the Journal,
resent evidence collected from implanted devices docu-
enting a diminished atrial arrhythmia burden after con-
erting the implanted device from conventional pacing to
ne providing cardiac resynchronization. The improvement
n arrhythmia burden parallels an improvement in ventric-
lar function and geometry. If these initial observations
rove consistent, we might have to add an atrial antiarrhyth-
ic effect to the list of benefits of cardiac resynchronization.
See page 1246
Clinical observations suggest a physiologic link between
eterioration in ventricular function and increased atrial
brillation (AF) and flutter. Historically, CHF increases the
isk of AF (2). Mitral regurgitation also commonly leads to
trial arrhythmia. Logic follows that increased left ventric-
lar filling pressure and mitral regurgitation produce atrial
tretch that accelerates fibrosis, apoptosis, and heterogeneity
n atrial conduction that create a substrate for atrial arrhyth-
ia. Experimental models support this association (3). As
ardiac function and geometry worsen, the likelihood of AF
ncreases; the loss of atrial transport with compromised
entricular filling and pre-load in turn aggravate an already
enuous hemodynamic state, perpetuating a vicious cycle
raught with adverse consequences (4,5). Furthermore, a his-
ory of CHF and left ventricular dysfunction in a patient with
F increases the risk of thromboembolic stroke. Thus recur-
Editorials published in the Journal of American College of Cardiology reflect the views
f the authors and do not necessarily represent the views of JACC or the American
ollege of Cardiology.i
From Emory University School of Medicine, Cardiology, The Carlyle Fraser Heart
enter, Atlanta, Georgia.ent atrial arrhythmia not only marks the worsening of ven-
ricular dysfunction but also contributes further to symptoms
nd undesirable outcomes, including death, increased hospital
tays, a need for cardioversion and antiarrhythmic drug ther-
py, and a requirement for warfarin anticoagulation.
Clinicians have few tools to effectively combat AF in the
eart failure patient. The risk of proarrhythmia in patients
ith left ventricular dysfunction precludes the use of Class
antiarrhythmic agents. The Class III drugs approved for
se by the U.S. Food and Drug Administration (sotalol and
ofetilide) might be safer but have limited efficacy in
aintaining sinus rhythm in CHF; use of each requires
n-hospital initiation of therapy, and the beta-blocking
ffect of sotalol might interfere with use of proven standard
eta-blockade. The old stand-by, amiodarone, lacks U.S.
ood and Drug Administration approval for this purpose
nd carries a substantial risk of organ toxicity with pro-
onged use. In practice, it might remain the most frequently
sed antiarrhythmic drug for treating AF in the CHF
opulation. Recent reports on the efficacy of catheter
blation in selected patients with CHF and left ventricular
ysfunction raise enthusiasm for this technique (6,7). How-
ver, primary ablation must stand the test of time and more
ontrolled study before one can advocate its widespread use
n patients with moderate to sever heart failure, particularly
y operators with limited expertise. Catheter ablation of the
trioventricular junction provides rate control for the patient
ith persistent or permanent AF and rapid ventricular
onduction, and ventricular function might improve after
ate control. However, the loss of atrial transport and
bligatory right ventricular pacing after ablation might
ctually worsen CHF in individuals with AF and left
entricular dysfunction not due to inadequate rate control.
herefore, in most CHF patients, our treatment of AF
onsists of warfarin anticoagulation, antiarrhythmic drug
herapy (usually with amiodarone) and direct current car-
ioversion to maintain sinus rhythm in those with paroxys-
al or persistent arrhythmia, or controlling atrioventricular
onduction in those with persistent/permanent AF who
ave no other choice.
A reduction in arrhythmia represents a significant bonus
rom any therapy that improves cardiac function. Ventric-
lar reverse remodeling resulting from afterload reduction
nd/or beta-receptor blockade could also promote reverse
trial remodeling and decrease atrial arrhythmia. However,
he large multicenter trials of afterload-reducing drugs and
eta-blockers in heart failure could not systematically ana-
yze the effect on atrial arrhythmia, given the absence of
mplanted devices with monitoring capability. Theoretically,
ess atrial arrhythmia could account for some of the reduc-
ion in the frequency of hospital stays and improvement in
ymptoms seen in those studies, but such a conclusion
ould be highly speculative. The effect of CRT on ventric-
lar arrhythmia remains unclear. Stored data from devices
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September 25, 2007:1252–3 Editorial CommentnSync-ICD clinical evaluations showed no difference in
verall ventricular tachycardia/ventricular fibrillation events
etween active therapy and control groups (8). Yet, others
eported a decrease in ventricular arrhythmia (9). Certainly
he impressive effect of CRT on survival demonstrated in
he CARE-HF (Cardiac Resynchronization-Heart Failure)
rial suggests that improving ventricular function reduces
he long-term risk of sudden death (10).
Although the CRT trials used devices with some capa-
ility to detect and count atrial arrhythmia, almost all
ulticenter trials excluded patients with significant baseline
trial arrhythmia. Even in patients with atrial arrhythmia,
ot knowing the pre-implant arrhythmia burden prevents a
eaningful assessment of the impact of CRT. Nor can we
dequately compare the effect of CRT against a control
ithout an implanted device to gather post-implant ar-
hythmia data. Therefore, an analysis of AF from CARE
F could not adequately assess a change in arrhythmia
urden, given the absence of pre-implant data and the lack
f an implanted device to collect data in the control group
11). The many CRT trials focused on functional status,
xercise capacity, ventricular geometry and function, and
ventually mortality but not on atrial arrhythmia as a
rimary or secondary end point. Surely any future CRT trial
ould not likely include a period of observation for atrial
rrhythmia during inactive left ventricular stimulation for a
omparison of active CRT against a control. Thus, the data
rom observational studies with longitudinal comparisons,
ike the one discussed here, might provide the only oppor-
unity to examine the effect of CRT on atrial arrhythmia.
The results reported by Yannopoulos et al. (1) demon-
trate an impressive reduction in the frequency of atrial
rrhythmia after CRT. The observed effect might have
mportant clinical implications and raise other questions.
he potential for a reduction in atrial arrhythmia should
rompt postponement of atrioventricular junction ablation
r perhaps primary AF ablation for at least 3 months after
mplant in order to determine whether CRT alone might
educe the atria fibrillation burden. One might also wish to
econsider the use of previously ineffective antiarrhythmic
herapy and cardioversion to prolong intervals of sinus
hythm in patients otherwise thought destined to remain in
ersistent atria fibrillation. Conversely, CRT could also
otentially reduce anti-arrhythmic drug use in heart failure
atients with paroxysmal AF who previously required drug
herapy to remain in sinus rhythm. This study did not
ystematically test the effect of reducing antiarrhythmic
rugs after an observed reduction in arrhythmic events after
RT. That would require prospective study in patients with
aroxysmal AF indicated for CRT, and it might provide
nteresting and valuable data. Could the apparent elimina-
ion of AF after CRT obviate the need for warfarin
nticoagulation in those patients with AF and CHF? The
umber of patients enrolled in this study and the duration of
ollow-up do not provide the opportunity for a propernswer. But, the ability to catalog the presence or, more
mportantly, the absence of AF or flutter might allow
econsideration of the need for anticoagulation. As we move
orward, should we adopt automatic arrhythmia detection
y implanted devices as the best way to measure the success
f therapies for AF, particularly when considering the
iscontinuation of anticoagulation as a potential goal of a
articular therapy?
Although the reduction in atrial arrhythmia seems im-
ressive, one cannot yet consider an ancillary antiarrhythmic
enefit of CRT as an independent indication for its in-
reased use in patients with CHF. The indications for CRT
ill still rest on its effect on ventricular function, mortality,
nd functional improvement. However, data such as those
resented by the authors allow one to conclude that the
onus effect of improving ventricular function through
ardiac resynchronization might provide an unanticipated
ut highly desirable anti-arrhythmic therapy. So, with
pologies to Vaughn-Williams, should we call it the Class
–CRT effect?
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mory University School of Medicine, Cardiology, The Carlyle
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